Sanofi signed a collaboration with Earendil Labs worth up to $2.56 billion to discover and develop bispecific antibodies for autoimmune and inflammatory diseases using Earendil’s AI-driven discovery platform. The deal includes upfront and milestone payments and aims to accelerate candidate identification via predictive protein modeling coupled with high‑throughput validation. Earendil will deploy its AI models to nominate bispecific candidates; Sanofi will lead clinical development and global commercialization. Both companies emphasized the arrangement’s potential to improve discovery timelines and increase the throughput of bispecific programs. The pact is part of a broader wave of pharma partnering with AI discovery firms to de-risk early target selection and speed progression from concept to IND.